Novo Nordisk Shares Surge Following Promising Trial Results for Weight-Loss Drug
Prime Highlights: The company’s stock rose significantly after promising results from an early-stage trial of
M42 Strengthens Position as Middle East’s Largest Healthcare Firm with New Restructure and Expansion Plans
Prime Highlights: M42, the Middle East’s largest healthcare company, introduces a new operational structure to
FDA Expands Approval for J&J’s Spravato as Standalone Depression Treatment
Prime Highlights: The FDA has approved Johnson & Johnson’s Spravato (esketamine) nasal spray for standalone
AI-Designed Proteins Show Promise in Neutralizing Snake Venom Toxins
Prime Highlights: Researchers led by 2024 Nobel Laureate David Baker develop AI-designed proteins that neutralize
Drug in Clinical Trials for Breast Cancer Shows Promise for Treating Blood Cancers
Prime Highlights: Washington University research identifies a potential new use for an existing drug. RSK1
Medicare’s $2,000 Cap on Out-of-Pocket Drug Costs Set to Offer Significant Savings AARP Reports
Prime Highlights: Medicare’s new $2,000 cap on out-of-pocket prescription drug costs could save patients thousands.
UnitedHealth Surpasses Profit Expectations in Q4 Driven by Strong Health Services Performance
Prime Highlights: UnitedHealth reports Q4 earnings of $6.81 per share, exceeding estimates of $6.72. Health
Pfizer to Sell $3 Billion Stake in Haleon Reducing Ownership to 7.3%
Prime Highlights: Pfizer to sell $3.05 billion worth of shares in Haleon, reducing its stake
Eli Lilly to Acquire Scorpion Therapeutics’ Cancer Therapy for Up to $2.5 Billion
Prime Highlights: Eli Lilly to acquire Scorpion Therapeutics’ experimental cancer therapy, STX-478, for up to
Telix Pharmaceuticals Acquires ImaginAb for $73 Million to Expand Antibody Engineering Capabilities
Prime Highlights: Telix secures a US$45 million ($73 million) deal to acquire US-based antibody engineering
DBAY Advisors to Acquire Alliance Pharma in $430 Million All-Cash Deal
Prime Highlights: DBAY Advisors, an asset management firm, has agreed to acquire UK-based Alliance Pharma
Medicare to Cover Eli Lilly’s Zepbound for Sleep Apnea Treatment
Prime Highlights: Medicare will now cover Eli Lilly’s Zepbound for obstructive sleep apnea, following FDA
